Regulatory approval

Published by the European Medicines Agency. Approved

The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).

This is written in the approval document as:

ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).

Citation

Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised March 2026. Accessed August 2, 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2023-10-12	European Medicines Agency	Indication received approval from the European Commission.